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Abstract
 
TREM-2 is an immunoglobulin-like cell surface receptor associated with DAP12/KARAP
that activates monocyte-derived dendritic cells (DCs) in vitro. Recently, it has been shown that
genetic defects of human DAP12/KARAP and TREM-2 result in a rare syndrome character-
ized by bone cysts and presenile dementia called Nasu-Hakola disease. This observation suggests
that TREM-2 may function in myeloid cells other than DCs, most probably osteoclasts (OCs)
and microglial cells, which are involved in bone modeling and brain function. Consistent with
this prediction, here we show that OC differentiation is dramatically arrested in TREM-2–
deficient patients, resulting in large aggregates of immature OCs that exhibit impaired bone
resorptive activity. These results demonstrate a critical role for TREM-2 in the differentiation
of mononuclear myeloid precursors into functional multinucleated OCs.
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Introduction 
 
Triggering receptors expressed on myeloid cells (TREM)
are members of the immunoglobulin superfamily that
promote myeloid cell activation by associating with the
transmembrane adaptor protein DAP12/KARAP (1–4).
DAP12 contains an immunoreceptor tyrosine-based acti-
vation motif that functions as docking site for the protein
tyrosine kinases Syk and Zap70 (5, 6). These kinases me-
diate a cascade of phosphorylation events that ultimately
activate the cell. Within the TREM receptor family,
TREM-2 is selectively expressed on monocyte-derived
DCs and promotes DC migration and activation in vitro,
suggesting that it may have a role in antigen presentation
and T cell stimulation in vivo (2). Rare TREM-2– and
DAP12-deficient individuals have been recently identified
(7, 8). Remarkably, these individuals are affected by a genetic
syndrome characterized by bone cysts and presenile demen-
tia, called Nasu-Hakola disease or polycystic lipomembranous
osteodysplasia with sclerosing leukoencephalopathy (9). This
observation suggests that the TREM-2–DAP12 complex
may regulate the function of an unexpectedly vast array of
myeloid cells, including not only DCs, but also osteoclasts
(OCs) and microglial cells, which are critical for bone mod-
eling and brain function, respectively. In this study, we ex-
amined TREM-2 function in human OCs.
 
Materials and Methods
 
In Vitro Generation of OCs and DCs.
 
Monocytes were isolated
from PBMCs of Nasu-Hakola patients and healthy controls using
anti-CD14 microbeads (Miltenyi Biotec) and cultured in RPMI
supplemented with 10% FCS (Hyclone), nonessential amino ac-
ids, Na pyruvate, Glutamax, kanamycin (GIBCO BRL), 50 ng/
ml GM-CSF (Leukine; Immunex), and 1 ng/ml IL-4 (R&D Sys-
tems) or 10 ng/ml M-CSF (R&D Systems) for 48 h. To generate
OCs, cells were seeded in 24-well plates (3 
 
  
 
10
 
5
 
/well) or in
glass chamber slides (1.5 
 
  
 
10
 
5
 
/well; Lab-Tek; Nalgene) with
GM-CSF and IL-4. After 48 h the culture medium was supple-
mented with 300 ng/ml RANK-L, 10 ng/ml M-CSF, and the
anti–class II mAb 3.8B1 (1:10 dilution of culture supernatant).
Under these conditions, mature OC formation was observed after
7–10 d of culture. Generation of monocyte-derived DCs was
performed as previously described (10).
 
Immunoblot Analysis.
 
TREM-2–deficient or control DCs were
lysed at day 6 of culture. Cell lysates were run in 10% Tris-Glycine
gel (Novex) with MES running buffer (2 
 
  
 
10
 
5 
 
cells were loaded in
each lane). Gels were blotted onto nitrocellulose membranes and
incubated with anti–TREM-2 antibodies (clones 21E10 and 20G3)
or rabbit anti–DAP12 antiserum as previously described (2).
 
The online version of this article contains supplemental material.
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Flow Cytometry.
 
Monocytes were stained with anti–TREM-1
(mouse IgG1, clone 9E2), CD16 (mouse IgM, Dako), and CD14
(mouse IgG2b, TIB228). Monocyte-derived DCs and OC pre-
cursors were stained with anti–TREM-2 (mouse IgG1, clone
21E10), CD14, and CD16. PE- and FITC-labeled (Fab
 
 
 
)
 
2 
 
iso-
type-specific goat anti–mouse antibodies (Southern Biotechnol-
ogy Associates, Inc.) were used as second step antibodies. LPS-acti-
vated DCs were stained with PE-labeled CD1a, CD86, and
FITC-labeled CD83 and CD16 (Immunotech).
 
OC Phenotype.
 
OCs were stained in 24-well plates for tar-
trate-resistant acid phosphatase (TRAP) activity (Acid Phos-
phatase Kit; Sigma-Aldrich). To examine F-actin distribution,
cells were fixed for 10 min in 0.1% glutaraldehyde and 3.7%
formaldehyde, permeabilized for 5 min in 0.2% Triton X-100,
and stained with Phalloidin-Oregon Green (Molecular Probes). A
MRC-600/Biorad confocal microscope was used for analysis.
Expression of calcitonin receptor and vitronectin receptor was as-
sessed by RT-PCR. For this assay, OC RNA was prepared by
lysing cells in situ with TRIzol (GIBCO BRL) at the end of the
culture. Synthesis of cDNA and PCR were performed by
standard techniques. Primers for vitronectin receptor were: 5
 
 
 
-GTT-
GGGAGATTAGACAGAGG-3
 
  
 
and 5
 
 
 
-CTAGTGGGTCAA-
GATGTAGC-3
 
 
 
. Primers for calcitonin receptors were: 5
 
 
 
-ACT-
GCTGGCTGAGTGTGGAAA-3
 
 
 
, 5
 
 
 
-GAAGCAGTAGATGGT-
CGAAAC-3
 
  
 
(11). PCR products were run on a 1.5% agarose
gel and stained with ethidium bromide.
 
Resorption Assays.
 
Purified peripheral blood monocytes from
TREM-2–deficient patients and healthy donors were seeded on
either BD Biocoat™
 
 
 
Osteologic™
 
 
 
Multitest Slides (BD Bio-
sciences) or dentin slices (Alpco Diagnostics). Cells were seeded
at 0.6–1.5 
 
  
 
10
 
5
 
/well and cultured with GM-CSF and IL-4. Af-
ter 48 h, culture medium was supplemented with receptor activa-
tor of NF-
 
 
 
B ligand (RANKL), mAb 3.8B1, and M-CSF. After
10–12 d, dentin slices were treated with 2 N sodium hydroxide
to remove cells, washed with distilled water, stained with hema-
toxylin, and examined by light microscopy. Cells were removed
from Biocoat™
 
 
 
slides with 5% sodium hypochlorite. Slides were
washed with distilled water, air-dried, examined by light micros-
copy, and reexamined after Von Kossa staining, as described by
the manufacturer (BD Biosciences).
 
Online Supplemental Material.
 
TREM-2–deficient immature
osteoclasts degrade thin calcium phosphate layers. Monocytes
from TREM-2–deficient patients (a–c) or healthy individuals (d–
f) were cultured on thin films of calcium phosphate coated onto
quartz slides. At day 10, cultures were inspected by light micros-
copy (a, b, d, and e) before (a and d) and after (b and e) cell re-
moval. In b and e, lacunae were directly visualized by light mi-
croscopy (
 
 
 
2); in c and f, lacunae were detected after Von Kossa
staining of slides (
 
 
 
10). Resorption areas appear as clear spots
with a contrasting brown/black background. The exaggerated
ability of TREM-2–deficient immature osteoclasts to degrade
thin calcium phosphate layers suggests active phagocytic activity
and ability to acidify the medium. Fig. S1 is available at http://
www.jem.org/cgi/content/full/jem.20022220/DC1.
 
Results
 
TREM-2 Is Expressed on OC Precursors.
 
OCs are polykary-
ons of the monocyte/macrophage lineage that specialize in
bone resorption (12, 13). They derive from the fusion of
mononuclear myeloid precursors (14, 15) in the presence
of two key cytokines: M-CSF and a TNF-related protein,
RANKL (also known as OPGL, TRANCE, or ODF; 12).
Osteoclastogenesis is also promoted by inflammatory cyto-
kines, such as TNF-
 
  
 
and IL-1, which activate the tran-
scription factor NF-
 
 
 
B (12), and by fusion regulatory pro-
teins, such as CD98 (16). To generate human OCs in vitro,
we used peripheral blood monocytes as precursors and cul-
tured them with GM-CSF and IL-4 for the first 48–72 h.
Cell culture medium was then supplemented with M-CSF,
RANKL, and the anti–HLA-DR mAb 3.8B1, which de-
livers a potent myeloid cell activation signal by stimulating
protein tyrosine phosphorylation (10). In these culture
conditions, monocytes clustered in large aggregates and
fused to form multinucleated cells with typical OC fea-
tures. In control cultures, monocytes were maintained in
GM-CSF and IL-4 to generate monocyte-derived DCs.
Both culture conditions induced expression of TREM-2
on monocytic precursors, as did M-CSF, GM-CSF, and
IL-4 alone (Fig. 1). Within 12 h after the addition of mAb
3.8B1 and RANKL, differentiating progenitors reduced
cell surface expression of TREM-2 to low but detectable
levels (not depicted).
 
Incomplete Differentiation of TREM-2–deficient Monocytes
into OCs.
 
To define the role of TREM-2 in OC func-
tion, we examined OCs from two TREM-2–deficient pa-
tients. Patients A and B have been previously shown to
carry a homozygous mutation of the splice donor consensus
site of intron 3 of the TREM-2 gene (8). This mutation re-
sults in the skipping of exon 3 (and perhaps additional ex-
ons) from the TREM-2 mature mRNA, most likely im-
pairing cell surface expression of TREM-2. Indeed, OC
precursors and monocyte-derived DCs from patients A and
B expressed very little TREM-2 on the cell surface in
Figure 1. Monocytic precursors from normal donors express TREM-2
at early times of culture with M-CSF or GM-CSF and IL-4. TREM-2 is
expressed within 48–72 h of culture with M-CSF or GM-CSF and IL-4,
reaching a maximum level at days 3–4. It is worth noting that IL-4 alone
is sufficient to induce TREM-2 expression, consistent with a possible role
of Th2 cytokines in regulation of TREM-2.T
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comparison to those cultured from normal donors (Fig. 2, a
and b). Complete lack of expression was also observed in a
patient carrying a mutation of DAP12 that has been re-
cently characterized (Fig. 2 b; reference 17). To confirm
that patients A and B have a selective defect of TREM-2,
we analyzed another DAP12-associated receptor, TREM-1,
which is expressed on peripheral blood monocytes and
granulocytes. As shown in Fig. 2 c, TREM-1 was ex-
pressed on the monocytes of patient A and B, but not on
DAP12-deficient monocytes. Immunoblot analysis con-
firmed that lack of TREM-2 in patients A and B is associ-
ated with normal DAP12 expression (Fig. 2 d).
OCs were generated in vitro from peripheral blood
monocytes of patients and normal donors as described
above. Within 7–10 d, monocytes from normal donors dif-
ferentiated into multinucleated OCs that spread out and
tightly attached to culture dishes or slides and expressed the
intracellular TRAP (Fig. 3, a and c). In striking contrast,
TREM-2–deficient monocytes formed large aggregates of
mononuclear cells that although intensely positive for
TRAP, did not fuse to generate polykaryons, were unable to
spread, and remained loosely adherent to tissue culture slides
(Fig. 3, b and d). To quantify the defect of OC develop-
ment, we counted cells with three or more nuclei generated
after seeding 60,000 monocytic precursors in each of three
wells of a 96-well plate. Normal monocytes yielded 180 
 
 
 
20 multinucleated cells/well, most of which displayed eight
or more nuclei. TREM-2–deficient monocytes generated 4 
 
 
 
1 cells/well with no more than three nuclei. Thus, OC dif-
ferentiation is obviously arrested in TREM-2–deficient pa-
tients. This implies that TREM-2 expression is required
during osteoclastogenesis to generate a signal that promotes
activation and fusion of precursors into mature OCs.
To further document the defect in osteoclastogenesis in
TREM-2–deficient patients, we analyzed additional OC
features. To resorb bone, OCs adhere tightly to the bone
matrix, establishing a sealing zone (12, 13). This process in-
volves rearrangement of the actin cytoskeleton to form an
“actin ring.” The membrane enclosed by the actin ring
forms a ruffled border, which is specialized for secretion of
protons and lysosomal proteases that mediate bone resorp-
tion (13). Accordingly, OCs from normal donors exhibited
a well-developed actin cytoskeleton with actin rings and
podosomes (Fig. 3, e and g). In contrast, the actin cytoskel-
eton was barely detectable under the cell membrane in
TREM-2–deficient immature OCs (Fig. 3, f and h). To
quantify these differences in actin polymerization, OC pre-
cursors were stained with phalloidin, which binds to poly-
merized actin (F actin), and analyzed by flow cytometry. As
shown in Fig. 3 i, the amount of F actin was significantly
higher in normal than TREM-2–deficient OCs. This lack
of adequate actin polymerization and cytoskeleton organi-
zation is consistent with the inability of TREM-2–deficient
OCs to spread and adhere normally in tissue culture and
suggests that their capacity to adhere tightly to bone matrix
might be impaired in vivo. This hypothesis was further
corroborated by analysis of vitronectin receptor expression,
which has been implicated in OC adhesion and migration
as well as bone resorption (18–20). As shown in Fig. 3 j,
expression of the vitronectin receptor transcript was clearly
reduced in TREM-2–deficient OCs as compared with
normal OCs.
Figure 2. Patient A exhibits a selective lack of TREM-2 expression in
monocytes cultured with M-CSF or GM-CSF and IL-4. (a) TREM-2
and CD16 expression in monocytes cultured for 48 or 72 h in the presence
of M-CSF from normal or TREM-2–deficient patients. (b) TREM-2 and
CD1b expression on control, TREM-2–deficient, and DAP12-deficient
monocytes cultured for 4 d in GM-CSF and IL-4. (c) TREM-1 expres-
sion on freshly isolated monocytes from normal, TREM-2–deficient, and
DAP12-deficient individuals. (d) Expression of TREM-2 and DAP12
proteins in normal and TREM-2–deficient monocyte-derived DCs at day
6 of culture assessed by immunoblot. Similar results were obtained with
monocytes derived from patient B (not depicted).T
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The receptor for calcitonin is another typical OC
marker, as it distinguishes OCs from multinucleated giant
cell macrophages (21). Therefore, we analyzed calcitonin
receptor transcripts by RT-PCR and detected no expres-
sion in TREM-2–deficient OC, whereas this receptor was
expressed in normal mature OCs (Fig. 3 j). Together with
the lack of actin polymerization and cell polarization, this
observation confirms the defect in osteoclastogenesis in
TREM-2–deficient patients.
 
Impaired Resorptive Function of TREM-2–deficient OCs.
 
To test the impact of defective osteoclastogenesis on re-
sorptive function, OCs from normal donors and TREM-
2–deficient patients were cultured on dentin slices and the
lacunae resulting from resorption were analyzed by light
microscopy (Fig. 4). In parallel experiments, resorption was
also analyzed on thin films of calcium phosphate coated
onto quartz slides (see Fig. S1, available at http://www.
jem.org/cgi/content/full/jem.20022220/DC1). Normal OCs
created limited and well-defined excavations in the dentin
slices and calcium phosphate surface that corresponded to
the polykaryons (Fig. 4 and Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20022220/DC1). In strik-
ing contrast, TREM-2–deficient immature OCs were inca-
pable of excavating resorptive pits on dentin slices (Fig. 4).
Figure 3. Arrest of differentiation, defect of actin polymerization, reduced levels of vitronectin receptor (VNR), and lack expression of calcitonin re-
ceptor (CTR) in OCs from TREM-2–deficient patients. (a–d) Images of OC cultures derived from normal (a and c) and TREM-2–deficient individuals
(b and d). Images were taken on a Nikon phase contrast microscope with a 10DL objective. In c and d, cells were stained for intracellular TRAP. Upon
stimulation with M-CSF, RANKL, and mAb 3.8B1, TREM-2–deficient monocytic precursors do not fuse, but form large aggregates of cells intensely
positive for the TRAP reaction. Multinucleated cells with up to three nuclei were rarely detected in the OC cultures from TREM-2–deficient patients
(red arrow). (e–h) Actin cytoskeleton of OCs from normal (e and g) and TREM-2–deficient individuals (f and h) generated in glass chamber slides,
stained on day 10 of culture with Phalloidin-Oregon Green and analyzed by confocal microscopy ( 20). (i) Content of F actin/cell was determined in
control and TREM-2–deficient cells by flow cytometry 48 h after stimulation of monocytes with M-CSF, RANKL, and the 3.8B1 mAb. At this early
time point immature OCs could still be recovered from culture wells. (j) Three-fold dilutions of cDNAs obtained from control OC cultures, control
monocytes, or TREM-2–deficient OC cultures were amplified by RT-PCR with oligonucleotide pairs specific for vitronectin receptor (VNR), cal-
citonin receptor (CTR), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). PCR products were separated by agarose gel electrophoresis and
visualized with ethidium bromide. Molecular weight markers are indicated.T
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Only a few pits were detected that corresponded in num-
ber to the few multinucleated cells generated (Fig. 4). Un-
expectedly, TREM-2–deficient immature OCs excavated
numerous and large resorptive areas on calcium phosphate
film that appeared to correspond to the large cellular aggre-
gates formed in culture by immature OCs (Fig. S1, available
at http://www.jem.org/cgi/content/full/jem.20022220/
DC1). Thus, immature OCs derived from TREM-2–defi-
cient individuals resorb bone matrix very inefficiently.
However, they actively degrade thin calcium phosphate
layers, possibly through phagocytic and acidification mech-
anisms.
 
TREM-2–deficient Monocytes Reluctantly Differentiate into
DCs.
 
In parallel with our examination of OC differentia-
tion, we analyzed differentiation of TREM-2–deficient
monocytes into DCs (22). Monocytes from normal donors
maintained in GM-CSF/IL-4 for 4–6 d differentiated into
DCs expressing high levels of CD1a. Remarkably, TREM-
2–deficient monocytes differentiated into two distinct cell
subsets: a small subset expressing the DC marker CD1a and
a larger population expressing the macrophage marker
CD16 but lacking CD1a (Fig. 5). Only after 7 or more
days of culture in GM-CSF and IL-4 did TREM-2–defi-
cient monocytes acquire the CD1a
 
  
 
CD16
 
  
 
phenotype
typical of monocyte-derived DCs (not depicted). Upon
stimulation with LPS, TREM-2–deficient DCs did up-
regulate the costimulatory molecules CD86 and CD83,
showing normal responsiveness to activation stimuli (Fig.
5). Thus, TREM-2–deficient monocytes favor a macro-
phage differentiation pathway. Only a prolonged treatment
with GM-CSF and IL-4 overcomes this bias, eventually
driving differentiation toward a DC pathway.
 
Discussion
 
Our study shows that TREM-2–deficient individuals
have a striking defect in OC development, which results in
impaired bone resorption in vitro. TREM-2–deficient OC
precursors fail to fuse into multinucleated cells, do not de-
velop extensive rearrangements of actin cytoskeleton, and
show reduced or no expression of typical OC markers such
as vitronectin and calcitonin receptors. TREM-2–deficient
immature OCs do express TRAP; however, this molecule
is also expressed in other bone marrow–derived cells. This
block in OC development leads to impaired performance
in dentin resorption assays, potentially reflecting inefficient
bone resorption in vivo. It will be important to determine
how this defect contributes to the development of cysts and
spontaneous fractures in bones of Nasu-Hakola disease pa-
tients (9). Consistent with our results, defective develop-
ment and resorptive function of OCs have been recently
observed in DAP12-deficient mice (23). Thus, TREM-2/
DAP12 is an essential element in a unique pathway of bone
remodeling and repair, which cooperates with previously
defined OC differentiation pathways (12).
Figure 4. Impaired resorptive function of TREM-2–deficient imma-
ture OCs. Resorptive function of normal and TREM-2–deficient OCs
on dentin slices (a–f). Monocytic precursors from healthy individuals (a
and b) and TREM-2–deficient patients (c–f) were cultured on dentin
slices. At day 10, dentin slices were stained with hematoxylin and in-
spected by light microscopy before (a, c, and e) and after (b, d, and f) cell
removal. Resorption pits appear as dark spots stained with hematoxylin
after cell removal. Normal monocytes differentiated into multinucleated
OCs (a) that generated resorption pits (b). In general, TREM-2–deficient
mononuclear immature OCs (c) did not excavate resorptive pits (d). Only
a few pits were detected (f) that corresponded in number to the few
multinucleated cells generated (e).
Figure 5. A subset of TREM-2–deficient DCs expresses the macro-
phage marker CD16. Immature DCs from normal (top panels) and
TREM-2–deficient individuals (bottom panels) were generated by cultur-
ing peripheral blood monocytes with GM-CSF and IL-4. At day 4, DCs
were analyzed for expression of CD1a, CD16, CD83, and CD86. A
population of CD1a  CD16  macrophage-like cells was detected in the
cultures of TREM-2–deficient patient A but not in control cultures.
Identical results were obtained from DC cultures of patient B (not de-
picted). DC activation was monitored 24 h after stimulation with LPS.
CD86 and CD83 were up-regulated on LPS-activated DCs in both
TREM-2–deficient and control DC.T
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More generally, TREM-2 appears to play a major role in
regulating myeloid lineage development. Our data are con-
sistent with the hypothesis that TREM-2, by interacting
with a yet unknown ligand on myeloid precursors or stro-
mal cells, generates a positive signal that promotes precur-
sor cell differentiation into OCs in the presence of M-CSF
and RANKL or into DCs in the presence of GM-CSF and
IL-4. In contrast, when TREM-2 is absent, myeloid cell
differentiation is biased toward the macrophage lineage.
Corroborating this, TREM-2–deficient monocytes are re-
luctant to differentiate into DCs and, if not driven by exog-
enous factors, favor the macrophage pathway. The exag-
gerated ability of TREM-2–deficient immature OCs to
degrade thin calcium phosphate layers is also consistent
with the retention of a phagocytic activity. This model
suggests an inherent flexibility in the myeloid development
program that is dependent on existing needs. Under ho-
meostatic conditions, engagement of TREM-2 may favor
OC differentiation, whereas inflammatory conditions may
drive myeloid differentiation toward the macrophage lineage
through engagement of different receptors. Accordingly, it
has been recently shown that engagement of Toll-like re-
ceptors by bacterial products or CpG oligonucleotides di-
rects OC differentiation toward a macrophage pathway
(28, 29). TREM-2 may guide myeloid cell differentiation
by modulating responsiveness to certain cytokines or rein-
forcing signaling pathways triggered by cytokine receptors
or integrins (19, 24–27). The TREM-2/DAP12 signaling
pathway may also play an important role in promoting ac-
tin polymerization, organization of the cytoskeleton, and
ruffled border trafficking via recruitment of protein tyro-
sine kinases, activation of phospholipase C
 
 
 
1, and calcium
mobilization (30). These functions are critical for promot-
ing cell fusion as well as transforming OC precursors into a
polarized cell type capable of resorbing bone in a highly
regulated fashion (13).
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